Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England

Clinical and Diagnostic Laboratory Immunology

Volumn 10, Issue 5, 2003, Pages 780-786

  Andrews, Nick ^a   Borrow, Ray ^b   Miller, Elizabeth ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b WITHINGTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; MENINGOCOCCUS VACCINE;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; EXPOSURE; GROUPS BY AGE; HUMAN; IMMUNOASSAY; IMMUNOLOGICAL MEMORY; INFANT; INFECTION PREVENTION; LICENSING; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RABBIT; REFERENCE VALUE; RELIABILITY; SEROLOGY; SEROTYPE; SERUM BACTERICIDAL ACTIVITY; SERUM BACTERICIDAL ANTIBODY ASSAY; STATISTICAL SIGNIFICANCE; UNITED KINGDOM; VACCINATION; VALIDATION PROCESS;

CHILD; CHILD, PRESCHOOL; ENGLAND; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; POPULATION SURVEILLANCE; REFERENCE VALUES; SERUM BACTERICIDAL TEST; TIME FACTORS; TREATMENT OUTCOME;

EID: 0141675219     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.10.5.780-786.2003     Document Type: Article

References (19)

1. Biselli, R., A. Fattorossi, P. M. Matricardi, R. Nisini, T. Stroffolini, and R. d'Amelio. 1993. Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination. Vaccine 11:578-581.
2. Borrow, R., N. Andrews, D. Goldblatt, and E. Miller. 2001. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: a re-evaluation of correlates of protection. Infect. Immun. 69: 1568-1573.
3. Borrow, R., and G. M. Carlone. 2001. Serogroup B and C serum bactericidal assays, p. 289-304. In A. J. Pollard and M. C. J. Maiden (ed.), Meningococcal vaccines. Methods in molecular medicine. Humana Press, Totowa, N.J.
4. Burrage, M., A. Robinson, R. Borrow, N. Andrews, J. Southern, J. Findlow, S. Martin, C. Thornton, D. Goldblatt, M. Corbel, D. Sesardic, K. Cartwright, P. Richmond, and E. Miller. 2002. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect. Immun. 70:4946-4954.
5. De Wals, P., M. Dionne, M. Douville-Fradet, N. Boulianne, J. Drapeau, and G. de Serres. 2001. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 285:177-181.
6. Espin Rios, I., A. Garcia-Fulgueiras, J. A. Navarro Alonso, J. Vazquez Moreno, T. Rodriguez Gonzalez, C. Navarro Sanchez, and D. Perez-Flores. 2000. Seroconversion and duration of immunity after vaccination against group C meningococcal infection in young children. Vaccine 18:2656-2660.
7. Farrington, C. P. 1995. Estimation of vaccine effectiveness using the screening method. Int. J. Epidemiol. 22:742-746.
8. Gold, R., and M. S. Artenstein. 1971. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull. W. H. O. 45:279-282.
9. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
10. Griffiss, J. M., and D. K. Goroff. 1983. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms by separate molecular mechanisms. J. Immunol. 130:2882-2885.
11. Maslanka, S. E., L. L. Gheesling, D. E. LiButti, K. B. J. Donaldson, H. S. Harakeh, J. K. Dykes, F. F. Arhin, S. J. N. Devi, C. E. Frasch, J. C. Huang, P. Kris-Kuzemenska, R. D. Lemmon, M. Lorange, C. C. A. M. Peeters, S. Quataert, J. Y. Tai, and G. M. Carlone. 1997. Standardization and a multilaboratory comparison of Neissoria meningitidis serogroup A and C serum bactericidal assays. Clin. Diagn. Lab. Immunol. 4:156-167.
12. Miller, E., D. Salisbury, and M. Ramsay. 2002. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20:S58-S67.
13. Ramsay, M. E., N. Andrews, E. B. Kaczmarski, and E. Miller. 2001. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357:195-196.
14. Richmond, P., R. Borrow, D. Goldblatt, J. Findlow, S. Martin, R. Morris, K. Cartwright, and E. Miller. 2001. Ability of three different meningococcal C conjugate vaccines to induce immunological memory after a single dose in UK toddlers. J. Infect. Dis. 183:160-163.
15. Richmond, P., E. Kaczmarski, R. Borrow, J. Findlow, S. Clark, R. McCann, J. Hill, M. Barker, and E. Miller. 2000. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J. Infect. Dis. 181:761-764.
16. Richmond, P. C., E. Miller, R. Borrow, S. Clark, F. Sadler, A. J. Fox, N. T. Begg, R. Morris, and K. A. V. Cartwright. 1999. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis. 179:1569-1572.
17. Siber, G. R. 1997. Methods for estimating serological correlates of protection. Dev. Biol. Stand. 89:283-296.
18. Taunay, A. E., R. A. Feldman, C. O. Bastos, P. A. A. Galvao, J. S. Morais, and I. O. Castro. 1978. Avaliação do efeito protector de vacina polissacaridica antimenigococica da grupa C, em crianças de 6 a 36 meses. Rev. Inst. Adolfo Lutz 32:77-82. (In Portuguese.)
19. Trotter, C., N. Andrews, R. Borrow, and E. Miller. 2003. Seroprevalence of meningococcal serogroup C antibody in England and Wales in the prevaccination era. Vaccine 21:1094-1098.